RadNet to Acquire iCAD for ~$103M
Shots:
- RadNet has entered into a definitive merger agreement to acquire iCAD in an all-stock transaction, through which iCAD will become a wholly owned subsidiary of RadNet
- As per the deal, iCAD stockholders will receive 0.0677 RadNet shares/ iCAD share, representing transaction value of ~$103M, or ~$3.61/share (~98% premium) on a fully diluted basis; closing expected in Q2 or Q3’25
- Acquisition will integrate iCAD's AI-driven ProFound Breast Health Suite with RadNet's DeepHealth platform, expanding RadNet’s global reach through iCAD’s presence in over 1,500 provider sites across 50+ countries
Ref: Globenewswire | Image: iCAD
Related News:- Siemens to Acquire Dotmatics for $5.1B, Strengthening its Position in Life Science Market
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
